These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 18042002

  • 1. Huntington's disease: progress and potential in the field.
    Stack EC, Ferrante RJ.
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1933-53. PubMed ID: 18042002
    [Abstract] [Full Text] [Related]

  • 2. Emerging chemotherapeutic strategies for Huntington's disease.
    Ryu H, Ferrante RJ.
    Expert Opin Emerg Drugs; 2005 May; 10(2):345-63. PubMed ID: 15934871
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JC, Jansson EK, Eckert GP, Pichler BJ, Bordet T, Pruss RM, Riess O, Nguyen HP.
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [Abstract] [Full Text] [Related]

  • 8. Society for Neuroscience--38th Annual Meeting--Focus on Huntington's disease.
    Gotham S.
    IDrugs; 2009 Jan; 12(1):12-3. PubMed ID: 19127497
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Huntington's disease: clinical characteristics, pathogenesis and therapies.
    Nakamura K, Aminoff MJ.
    Drugs Today (Barc); 2007 Feb; 43(2):97-116. PubMed ID: 17353947
    [Abstract] [Full Text] [Related]

  • 12. Antioxidants in Huntington's disease.
    Johri A, Beal MF.
    Biochim Biophys Acta; 2012 May; 1822(5):664-74. PubMed ID: 22138129
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F, Fischhaber PL, Guo C, Tang TS.
    Epigenomics; 2014 Jun; 6(3):287-97. PubMed ID: 25111483
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Régulier E, Bates GP, Paganetti P.
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [Abstract] [Full Text] [Related]

  • 17. Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.
    Díaz-Hernández M, Torres-Peraza J, Salvatori-Abarca A, Morán MA, Gómez-Ramos P, Alberch J, Lucas JJ.
    J Neurosci; 2005 Oct 19; 25(42):9773-81. PubMed ID: 16237181
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F, La Rosa S, Gonzalez-Couto E, Gaviraghi G, Terstappen GC.
    IDrugs; 2008 Sep 19; 11(9):653-60. PubMed ID: 18763216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.